KMT2D and melanoma: Other study has shown that KMT2D deficiency sensitizes different types of syngeneic tumors (including lung tumor, bladder tumor, breast tumor, and melanoma) to anti-PD1 [49], suggesting that anti-PD1 may have a stronger inhibitory effect on KMT2D-mutant tumors than on KMT2D-WT tumors.